These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 1720438)

  • 1. Benign prostatic hyperplasia: pathogenesis and medical therapy.
    Geller J
    J Am Geriatr Soc; 1991 Dec; 39(12):1208-16. PubMed ID: 1720438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonsurgical treatment of prostatic hyperplasia.
    Geller J
    Cancer; 1992 Jul; 70(1 Suppl):339-45. PubMed ID: 1376202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis and medical treatment of benign prostatic hyperplasia.
    Geller J
    Prostate Suppl; 1989; 2():95-104. PubMed ID: 2482776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of benign prostatic hypertrophy.
    Geller J
    Urology; 1989 Oct; 34(4 Suppl):57-63; discussion 87-96. PubMed ID: 2477935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
    Krieg M; Bartsch W; Thomsen M; Voigt KD
    J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Steroid hormones and the pathogenesis of benign prostatic hyperplasia.
    Griffiths K; Eaton CL; Harper ME; Peeling B; Davies P
    Eur Urol; 1991; 20 Suppl 1():68-77. PubMed ID: 1722166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Vis AN; van Moorselaar RJ; Bui HN; Blankenstein MA; Meuleman EJ; Heijboer AC
    BJU Int; 2012 Jan; 109(2):176-82. PubMed ID: 21992222
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of dihydrotestosterone in benign prostatic hyperplasia.
    Carson C; Rittmaster R
    Urology; 2003 Apr; 61(4 Suppl 1):2-7. PubMed ID: 12657354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Benign prostatic hyperplasia--the outcome of age-induced alteration of androgen-estrogen balance?].
    Weisser H; Krieg M
    Urologe A; 1997 Jan; 36(1):3-9. PubMed ID: 9123678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in dihydrotestosterone metabolism and the development of benign prostatic hyperplasia in the aging beagle.
    Isaacs JT
    J Steroid Biochem; 1983 Jun; 18(6):749-57. PubMed ID: 6191128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate.
    Krieg M; Nass R; Tunn S
    J Clin Endocrinol Metab; 1993 Aug; 77(2):375-81. PubMed ID: 7688377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of sex steroid hormones in benign prostatic hyperplasia.
    Asiedu B; Anang Y; Nyarko A; Doku DA; Amoah BY; Santa S; Ngala RA; Asare GA
    Aging Male; 2017 Mar; 20(1):17-22. PubMed ID: 28084142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of dutasteride on intraprostatic dihydrotestosterone concentrations in men with benign prostatic hyperplasia.
    Wurzel R; Ray P; Major-Walker K; Shannon J; Rittmaster R
    Prostate Cancer Prostatic Dis; 2007; 10(2):149-54. PubMed ID: 17189955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cynomorium songaricum Rupr demonstrates phytoestrogenic or phytoandrogenic like activities that attenuates benign prostatic hyperplasia via regulating steroid 5-α-reductase.
    Tao R; Miao L; Yu X; Orgah JO; Barnabas O; Chang Y; Liu E; Fan G; Gao X
    J Ethnopharmacol; 2019 May; 235():65-74. PubMed ID: 30708032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.
    van der Sluis TM; Meuleman EJ; van Moorselaar RJ; Bui HN; Blankenstein MA; Heijboer AC; Vis AN
    BJU Int; 2012 Jan; 109(2):183-8. PubMed ID: 21992404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia.
    Isaacs JT; Coffey DS
    Endocrinology; 1981 Feb; 108(2):445-53. PubMed ID: 6161001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxytocin and prostatic function.
    Nicholson HD; Jenkin L
    Adv Exp Med Biol; 1995; 395():529-38. PubMed ID: 8714010
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-month treatment with a long-acting gonadotropin-releasing hormone agonist of patients with benign prostatic hyperplasia: effects on tissue androgen concentration, 5 alpha-reductase activity and androgen receptor content.
    Forti G; Salerno R; Moneti G; Zoppi S; Fiorelli G; Marinoni T; Natali A; Costantini A; Serio M; Martini L
    J Clin Endocrinol Metab; 1989 Feb; 68(2):461-8. PubMed ID: 2465302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.